NORTHRIDGE, Calif.—In an unpublished, peer-reviewed study reported in a poster at the Academy of Women's Health 2014 annual meeting in Washington, DC , a daily dose of S-equol (from Pharmavite LLC) showed no impact on reproductive or thyroid hormones or the menstrual cycles of premenopausal women.
The treatment period and post-treatment period lasted for one menstrual cycle in each subject. A daily does of a supplement containing 13.1 milligrams of S-equol did not significantly alter the levels of five reproductive and three thyroid hormones from pre-treatment levels, which remained in the normal range. The level also did not differ from levels in women receiving a placebo. Neither the supplement or the placebo affected the length of the women's menstrual cycles.
Blood samples were taken from each woman during the early follicular phase, about three to five days after the onset of their period, the late follicular phase, about 10 to 13 days after the onset and the luteal phase, about seven to 10 days after ovulation. The blood samples were repeated ruing the course of the three cycles. The women did not receive treatment in the first and last cycles, and received either a placebo or supplement during the middle cycle.
The complete data will be submitted to a peer-reviewed journal for publication.
S-equol is a compound that results from the natural metabolism of daidzien, an isoflavone found in whole soybeans. Not everyone can produce S-equol after soy consumption, as it depends on the types of bacteria in the large intestine. The S-equol ingredient is made under current Good Manufacturing Practices (cGMP) and has self-affirmed GRAS (generally recognized as safe) status.